Esophageal cancer future or investigational therapies

Esophageal cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Esophageal cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Esophageal cancer future or investigational therapies On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Esophageal cancer future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Esophageal cancer future or investigational therapies
CDC on Esophageal cancer future or investigational therapies
Esophageal cancer future or investigational therapies in the news
Blogs on Esophageal cancer future or investigational therapies
Directions to Hospitals Treating Esophageal cancer
Risk calculators and risk factors for Esophageal cancer future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]

Adavances in the treatment of esophageal cancer are focused on PET scanning for accurate staging and chemotherapeutics such ascapecitabine (Xeloda), cisplatin (Platinol), and docetaxel (Docefrez, Taxotere).

References

Template:WikiDoc Sources